172 related articles for article (PubMed ID: 21843875)
1. Medicare costs for neovascular age-related macular degeneration, 1994-2007.
Day S; Acquah K; Lee PP; Mruthyunjaya P; Sloan FA
Am J Ophthalmol; 2011 Dec; 152(6):1014-20. PubMed ID: 21843875
[TBL] [Abstract][Full Text] [Related]
2. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
Erie JC; Barkmeier AJ; Hodge DO; Mahr MA
Ophthalmology; 2016 Jun; 123(6):1257-62. PubMed ID: 26976701
[TBL] [Abstract][Full Text] [Related]
3. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999.
Coleman AL; Yu F
Ophthalmology; 2008 Jan; 115(1):18-25. PubMed ID: 17572499
[TBL] [Abstract][Full Text] [Related]
4. Costs of newly diagnosed neovascular age-related macular degeneration among medicare beneficiaries, 2004-2008.
Qualls LG; Hammill BG; Wang F; Lad EM; Schulman KA; Cousins SW; Curtis LH
Retina; 2013 Apr; 33(4):854-61. PubMed ID: 23296047
[TBL] [Abstract][Full Text] [Related]
5. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
Day S; Acquah K; Mruthyunjaya P; Grossman DS; Lee PP; Sloan FA
Am J Ophthalmol; 2011 Aug; 152(2):266-72. PubMed ID: 21664593
[TBL] [Abstract][Full Text] [Related]
6. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries.
Lad EM; Hammill BG; Qualls LG; Wang F; Cousins SW; Curtis LH
Am J Ophthalmol; 2014 Sep; 158(3):537-43.e2. PubMed ID: 24857687
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries.
Curtis LH; Hammill BG; Qualls LG; DiMartino LD; Wang F; Schulman KA; Cousins SW
Am J Ophthalmol; 2012 Jun; 153(6):1116-24.e1. PubMed ID: 22321802
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file.
Brechner RJ; Rosenfeld PJ; Babish JD; Caplan S
Am J Ophthalmol; 2011 May; 151(5):887-895.e1. PubMed ID: 21310390
[TBL] [Abstract][Full Text] [Related]
9. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
Brown GC; Brown MM; Rapuano S; Boyer D
Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
[TBL] [Abstract][Full Text] [Related]
10. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration.
Holekamp NM; Liu Y; Yeh WS; Chia Y; Kiss S; Almony A; Kowalski JW
Am J Ophthalmol; 2014 Apr; 157(4):825-833.e1. PubMed ID: 24388973
[TBL] [Abstract][Full Text] [Related]
11. Estimating Medicare and Patient Savings From the Use of Bevacizumab for the Treatment of Exudative Age-related Macular Degeneration.
Rosenfeld PJ; Windsor MA; Feuer WJ; Sun SJJ; Frick KD; Swanson EA; Huang D
Am J Ophthalmol; 2018 Jul; 191():135-139. PubMed ID: 29655642
[TBL] [Abstract][Full Text] [Related]
12. Economic Value of Anti-Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States.
Mulligan K; Seabury SA; Dugel PU; Blim JF; Goldman DP; Humayun MS
JAMA Ophthalmol; 2020 Jan; 138(1):40-47. PubMed ID: 31725830
[TBL] [Abstract][Full Text] [Related]
13. Disease Burden in the Treatment of Age-Related Macular Degeneration: Findings From a Time-and-Motion Study.
Prenner JL; Halperin LS; Rycroft C; Hogue S; Williams Liu Z; Seibert R
Am J Ophthalmol; 2015 Oct; 160(4):725-31.e1. PubMed ID: 26142721
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
[TBL] [Abstract][Full Text] [Related]
15. Repeated intravitreal injections of antivascular endothelial growth factor in patients with neovascular age-related macular degeneration may increase the risk of ischemic optic neuropathy.
Chen YY; Chou P; Huang YF; Chien HJ; Wu YC; Lee CC; Huang LY; Chen HH
BMC Ophthalmol; 2019 Dec; 19(1):268. PubMed ID: 31888553
[TBL] [Abstract][Full Text] [Related]
16. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
[TBL] [Abstract][Full Text] [Related]
17. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
[TBL] [Abstract][Full Text] [Related]
18. Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health.
Moreno TA; Kim SJ
Semin Ophthalmol; 2016; 31(4):378-84. PubMed ID: 27116030
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Follow-up of Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Kung FF; Starr MR; Bui YT; Mejia CA; Bakri SJ
Ophthalmol Retina; 2020 Nov; 4(11):1047-1053. PubMed ID: 32439455
[TBL] [Abstract][Full Text] [Related]
20. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
